Intra-hepatic arterial drug delivery

Area of Science:

• Oncology
• Pharmacology
• Medical Imaging

Background:

• Hepatic arterial drug administration offers regional advantages for liver cancer treatment.
• Current therapies face challenges with extrahepatic metastases, limiting survival benefits.

Purpose of the Study:

• To review the pharmacokinetic rationale and enhancement techniques for hepatic arterial drug therapy.
• To discuss clinical trials of hepatic arterial therapy for hepatocellular carcinoma and colorectal liver metastases.
• To explore advanced monitoring techniques for optimizing drug delivery and future therapeutic strategies.

Main Methods:

• Review of pharmacokinetic principles and clinical trial data for hepatic arterial therapy.
• Discussion of techniques to enhance regional drug delivery.
• Utilizing 19F magnetic resonance spectroscopy and 18F-5-FU positron emission tomography (PET) for in vivo tumor pharmacokinetic monitoring.

Main Results:

• Regional hepatic arterial therapy demonstrates superior clinical response rates compared to systemic therapy.
• Overall survival is not significantly prolonged due to the frequent development of extrahepatic metastases.
• High-dose hepatic arterial 5-fluorouracil (5-FU) infusion is in Phase III trials to maximize systemic drug levels.

Conclusions:

• Hepatic arterial therapy shows promise in local tumor control but requires strategies to overcome systemic spread.
• Advanced imaging techniques like PET are crucial for assessing drug uptake and guiding future therapies.
• Future research will integrate PET monitoring into hepatic arterial pro-drug gene therapy for enhanced efficacy.